Myriad Genetics Inc. (MYGN): Today's Featured Diversified Services Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Myriad Genetics ( MYGN) pushed the Diversified Services industry lower today making it today's featured Diversified Services laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Myriad Genetics fell $0.97 (-3.5%) to $26.62 on heavy volume. Throughout the day, 4,549,705 shares of Myriad Genetics exchanged hands as compared to its average daily volume of 1,359,100 shares. The stock ranged in price between $26.51-$28.67 after having opened the day at $28.01 as compared to the previous trading day's close of $27.59. Other companies within the Diversified Services industry that declined today were: SmartPros ( SPRO), down 11.4%, General Employment ( JOB), down 11.1%, Cambium Learning Group ( ABCD), down 8.8% and National Research Corporation ( NRCIB), down 7.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.5 billion and is part of the services sector. The company has a P/E ratio of 20.4, above the S&P 500 P/E ratio of 17.7. Shares are up 17.5% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Myriad Genetics a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Envestnet ( ENV), down 9.7%, Fortune Industries ( FFI), down 8.4%, SPS Commerce ( SPSC), down 7.6% and ENGlobal Corporation ( ENG), down 7.3% , were all gainers within the diversified services industry with MasterCard Incorporated ( MA) being today's featured diversified services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the diversified services industry could consider iShares Dow Jones US Cons Services ( IYC) while those bearish on the diversified services industry could consider ProShares Ultra Short Consumer Sers ( SCC).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments